NMS Labs
3701 Welsh Road, PO Box 433A, Willow Grove, PA 19090-0437
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 05/20/2015 05:44
Last Report Issued 01/19/2015 11:53

88888
Clinical Example Report
Attn: IT Department
3701 Welsh Road
Willow Grove, PA 19090

Patient Name 4125B-POS
Patient ID 4125B-POS
Chain 15000130
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 15000130

Received 01/19/2015 11:48

Sample ID 15000130-001
Matrix Blood
Patient Name 4125B-POS
Patient ID 4125B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
4125B Rufinamide, Blood				
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)				
Rufinamide	50	mcg/mL	0.50	ELEVATED
Synonym(s): Banzel®; Inovelon				
Maintenance therapy with 45 mg/kg (approximately 1600 mg) daily rufinamide resulted in plasma concentrations ranging from 5.0 - 48 mcg/mL (n = 74).				
Trough plasma concentrations in groups of 129-133 patients maintained on twice-daily 400 or 800 mg doses for 3 months averaged 2.6 or 4.7 mcg/mL, respectively.				
The blood to plasma ratio of rufinamide is approximately 1.0				